We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Senate Panel Debates User Fees, Drug Safety
Senate Panel Debates User Fees, Drug Safety
March 16, 2007
The two lead sponsors of legislation on improving the FDA’s drug safety efforts told the agency that, while they don’t like the idea of industry fees paying for agency reviews, the way these funds are used can be changed to balance the quick approval of drugs with increased safety monitoring throughout a product’s life cycle.